CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Smith Robert Paul JR Chief Commercial Officer | Returned to the company · Stock Option (Right to Buy) | −562,500 | 0 | ||
| 2026-03-19 | Smith Robert Paul JR Chief Commercial Officer | Returned to the company · Stock Option (Right to Buy) | −572,000 | 0 | ||
| 2026-03-19 | Smith Robert Paul JR Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +562,500 | 562,500 | ||
| 2026-03-19 | Smith Robert Paul JR Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +572,000 | 572,000 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −562,500 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −572,000 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −487,500 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −162,500 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −126,667 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −40,000 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −22,784 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −9,167 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −30,000 | 0 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +562,500 | 562,500 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +572,000 | 572,000 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +487,500 | 487,500 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +162,500 | 162,500 |
Page 2 of 14 · 262 trades